New Triple-Drug attack shows promise for Hard-to-Treat breast cancer

NCT ID NCT05608252

Recruiting now Disease control Sponsor: Adrienne G. Waks Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with a type of advanced breast cancer called HR+/HER2-negative. It tests a new drug, VS-6766, combined with two standard drugs (abemaciclib and fulvestrant). The goal is to find the safest dose and see if the combination can shrink tumors or stop them from growing. About 63 participants will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HORMONE RECEPTOR POSITIVE BREAST CANCER HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institite
RECRUITING

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital Cancer Center
WITHDRAWN

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.